ICER assessed GSK's COPD inhalers, Trelegy Ellipta and Breo Ellipta, for Medicare price negotiations, highlighting their once-daily dosing and comparable net health benefits.

Does gabapentinoid use increase the risk of severe exacerbation in patients with chronic obstructive pulmonary disease (COPD) ...

The current model for managing chronic obstructive pulmonary disease (COPD) generally considers inhalers from the same therapeutic class to be clinically equivalent.1 When a long-acting muscarinic ...

Patients with COPD had better inhaler adherence when invited to enroll in a program that lowers cost sharing for maintenance inhalers and offers medication management services, according to results ...

For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 ...

A new study published in the CHEST journal found that ensifentrine, an innovative inhaled therapy, significantly reduces the ...

The Hailie Smartinhaler device has also been cleared for use with inhalers from other manufacturers ... directly to patients with asthma and COPD under a 510(k) over-the-counter clearance.

Vantage Market Research is pleased to announce the publication of its latest report, Asthma and COPD Drugs Market. This ...

The Institute for Clinical and Economic Review has prepared a special report on Trelegy and Breo, two therapies that treat ...

However, by considering patients' individual circumstances and taking the time to ensure that they use the appropriate inhaler and technique, everyone can benefit. Asthma and COPD have a huge ...

There are certain risk factors for COPD, including obesity and having type 2 diabetes. A new study has found that people who have type 2 diabetes who are treated with GLP-1 and SGLT-2 medications ...